Alendronate for the treatment of osteoporosis in men

New England Journal of Medicine

Volumn 343, Issue 9, 2000, Pages 604-610

  Orwoll, Eric ^a   Ettinger, Mark ^b   Weiss, Stuart ^c   Miller, Paul ^d   Kendler, David ^e   Graham, John ^f   Adami, Silvano ^g   Weber, Kurt ^h   Lorenc, Roman ⁱ   Pietschmann, Peter ^j   Vandormael, Kristel ^k   Lombardi, Antonio ^k  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Clin Res Center of South Florida   (United States)

^c S Diego Endocr and Medical Clinic   (United States)

^d Health Sciences Center and Colorado Center for Bone Research   (United States)

^e VANCOUVER GENERAL HOSPITAL   (Canada)

^f Ashford Cancer Centre   (Australia)

^g UNIVERSITY OF VERONA   (Italy)

^h UNIVERSITY OF GRAZ   (Austria)

ⁱ CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^j UNIVERSITY OF VIENNA   (Austria)

^k MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTRADIOL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TESTOSTERONE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; FEMUR NECK; GASTROINTESTINAL TOXICITY; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; STEROID BLOOD LEVEL; TREATMENT OUTCOME; VERTEBRA FRACTURE;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BODY HEIGHT; BONE DENSITY; CALCIUM; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; ESTRADIOL; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDES; PHOSPHATES; SPINAL FRACTURES; TESTOSTERONE;

EID: 0034739277     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200008313430902     Document Type: Article

References (24)

1. The prevention and treatment of osteoporosis
2. The economic and human costs of osteoporotic fracture
3. Osteoporosis in men
4. Hip fractures in the elderly: A world-wide projection
5. The prevalence of vertebral deformity in European men and women: The European Vertebral Osteoporosis Study
6. Management of male osteoporosis: Report of the UK Consensus Group
7. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
8. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
9. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
10. Prevention of nonvertebral fractures by alendronate: A meta-analysis
11. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
12. Prevalence of low femoral bone density in older U.S. adults from NHANES III
13. Universal standardization for dual x-ray absorptiometry: Patient and phantom cross-calibration results
14. Quality assurance for bone densitometry research studies: Concept and impact
15. Assessment of vertebral fractures in osteoporosis research
16. A comparison of morphometric definitions of vertebral fracture
17. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
18. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
19. Risedronate increases bone mass regardless of gender or underlying condition in patients taking corticosteroids
20. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients
21. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
22. Effect of alendronate sodium on bone mineral density in postmenopausal, osteoporotic black women of African American descent
23. Studies of the oral bioavailability of alendronate
24. Alendronate is an effective treatment for Paget's disease regardless of patient characteristics